Adjunctive treatment with the GLP-1 agonist semaglutide significantly reduces the antipsychotic-related cardiometabolic risk in individuals with schizophrenia spectrum disorders compared with placebo.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/semaglutide-lowers-antipsychotic-related-cardiometabolic-2025a1000yxa?src=rss
Author :
Publish date : 2025-12-12 13:00:00
Copyright for syndicated content belongs to the linked Source.
